LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LFMDP SEC filings page.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) reported $191.6M in revenue over the twelve months to Jun 30, 2026, up 19.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
LifeMD’s dominant mechanic is fixed-cost absorption: rapid revenue growth is narrowing operating losses while gross margins remain broadly unchanged.
Despite a reported net loss of-$11.2M in FY2025, operating cash flow remained positive at$8.3M , showing that accounting earnings and cash generation are measuring different aspects of the year. Free cash flow was also positive at$6.4M , although operating cash flow was lower than FY2024’s$17.5M , tempering the apparent improvement in cash conversion.
Operating margin improved from
Total liabilities fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock held $36.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $8.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock scores 85/100 among other emerging companies.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock had 48M shares outstanding at the end of fiscal year 2025, against 45M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock scores 50/100 among other emerging companies.
Not available for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock, and counted as zero in the overall score.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock reported revenue of $194.1M in fiscal year 2025, against $154.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock scores 59/100 among other emerging companies.
Not available for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock, and counted as zero in the overall score.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's cash, cash equivalents and investments came to $36.8M at the end of fiscal year 2025, against $47.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock scores 52/100 among other emerging companies.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock reported a net loss of $11.2M while generating $8.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock reported an operating loss of $7.7M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock generated $47.3M in revenue in Q2 2026. This represents a decrease of 3.5% from the same quarter a year earlier. Against the prior quarter it is down 5.7%.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's EBITDA was -$6.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 216.8% from the same quarter a year earlier. Against the prior quarter it is up 20.9%.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock reported -$7.1M in net income in Q2 2026. This represents a decrease of 337.4% from the same quarter a year earlier. Against the prior quarter it is up 20.2%.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock earned -$0.16 per diluted share (EPS) in Q2 2026. This represents a decrease of 220.0% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.
Cash & Balance Sheet
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock recorded an outflow of $7.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 188.9% from the same quarter a year earlier. Against the prior quarter it is down 2160.3%.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock held $25.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's gross margin was 88.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's operating margin was -15.1% in Q2 2026, reflecting core business profitability. This is down 10.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's net profit margin was -15.0% in Q2 2026, showing the share of revenue converted to profit. This is down 11.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's ROE was -88.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 29.9 percentage points.
Capital Allocation
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock invested $68K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 91.3% from the same quarter a year earlier. Against the prior quarter it is down 35.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
LFMDP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.3M-3.5% | $50.2M-1.4% | $34.0M+403.7% | $60.2M+13.0% | $49.0M-3.2% | $50.9M+15.3% | $6.7M-85.0% | $53.3M+38.0% |
| Cost of Revenue | $5.3M-22.7% | $5.9M-27.2% | $5.3M-21.6% | $7.4M+47.8% | $6.8M+36.1% | $8.1M+76.9% | $6.8M+27.0% | $5.0M+4.9% |
| Gross Profit | $42.0M-0.4% | $44.2M+3.5% | $28.6M+50803.1% | $52.8M+9.3% | $42.2M-7.6% | $42.8M+8.1% | -$56K-100.1% | $48.3M+42.6% |
| SG&A Expenses | $13.6M-5.5% | $15.2M+5.8% | $12.6M+109.3% | $16.6M-8.4% | $14.4M-22.0% | $14.3M-6.3% | $6.0M-61.4% | $18.1M+35.2% |
| Operating Income | -$7.1M-203.8% | -$8.9M-655.6% | -$2.2M+44.7% | -$2.0M+50.7% | -$2.3M+62.8% | -$1.2M+80.9% | -$3.9M-80.9% | -$4.0M+12.5% |
| EBITDA | -$6.8M-216.8% | -$8.6M-744.1% | -$2.1M+52.8% | -$1.4M+60.5% | -$2.1M+63.9% | -$1.0M+82.6% | -$4.5M-140.7% | -$3.6M+15.8% |
| Interest Expense | -$46K-106.9% | -$56K-112.2% | -$26K-104.3% | $262K-53.0% | $661K+24.3% | $464K-2.9% | $608K-2.4% | $559K-21.7% |
| Income Tax | N/A | N/A | N/A | $169K-27.3% | N/A | N/A | N/A | $233K |
| Net Income | -$7.1M-337.4% | -$8.9M-4727.9% | -$5.6M-113.2% | -$3.8M+18.3% | -$1.6M+76.4% | -$184K+97.3% | $42.8M+23.4% | -$4.7M+23.9% |
| EPS (Basic) | -$0.16-220.0% | -$0.20-900.0% | -$0.12+14.3% | -$0.10+23.1% | -$0.05+73.7% | -$0.02+89.5% | -$0.14-16.7% | -$0.13+35.0% |
| EPS (Diluted) | -$0.16-220.0% | -$0.20 | -$0.12+14.3% | -$0.10+23.1% | -$0.05+73.7% | -$0.02 | -$0.14-16.7% | -$0.13+35.0% |
| Diluted Shares (Avg) | 48M+7.6% | 47M | N/A | 46M+9.9% | 44M+7.5% | 43M | N/A | 42M+21.9% |
Not reported in any period shown, so not listed: R&D Expenses.
LFMDP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.9M-18.6% | $70.1M-4.7% | $70.4M-7.5% | $66.0M-9.1% | $73.6M+15.3% | $73.6M+19.8% | $76.1M+30.1% | $72.6M+78.3% |
| Current Assets | $42.1M-14.2% | $51.7M+3.5% | $51.8M-1.0% | $41.1M-15.6% | $49.0M+8.8% | $50.0M+12.5% | $52.4M+22.9% | $48.7M+95.5% |
| Cash & Equivalents | $25.1M-30.6% | $34.5M+0.2% | $36.8M+5.1% | $23.8M-36.7% | $36.2M+1.5% | $34.4M-2.0% | $35.0M+5.6% | $37.6M+145.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $3.0M-9.1% | $3.2M+7.1% | $2.8M-0.9% | $3.4M+29.7% | $3.3M+57.8% | $3.0M+25.0% | $2.8M+1.4% | $2.6M-30.2% |
| Accounts Receivable | $11.3M+53.6% | $9.9M-3.3% | $9.3M-11.0% | $9.2M+52.8% | $7.3M+29.3% | $10.2M+91.0% | $10.5M+66.9% | $6.0M+36.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $51.9M-29.0% | $55.1M-25.6% | $47.3M-43.5% | $62.6M-20.3% | $73.2M+11.1% | $74.0M+23.0% | $83.7M+58.1% | $78.5M+51.6% |
| Current Liabilities | $46.6M-26.6% | $49.6M-18.6% | $41.6M-38.3% | $56.7M-3.9% | $63.5M+23.0% | $60.9M+36.3% | $67.4M+93.8% | $59.0M+81.3% |
| Non-Current Liabilities | $5.3M-44.9% | $5.5M-58.0% | $5.7M-65.0% | $6.0M-69.6% | $9.7M-32.2% | $13.1M-15.3% | $16.3M-10.4% | $19.6M+1.6% |
| Long-Term Debt | N/A | N/A | N/A | N/A | $15.9M | N/A | N/A | N/A |
| Total Equity | $8.0M+546.9% | $15.0M+745.7% | $23.2M+354.9% | $1.3M+117.0% | -$1.8M+57.6% | -$2.3M-175.5% | -$9.1M-359.1% | -$7.7M+39.1% |
| Retained Earnings | -$246.1M-3.2% | -$238.3M-1.1% | -$228.6M+4.7% | -$247.8M-5.3% | -$238.5M-3.9% | -$235.6M-6.2% | -$239.9M-11.9% | -$235.4M-12.2% |
Not reported in any period shown, so not listed: Goodwill.
LFMDP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9M-180.2% | $445K-85.5% | -$3.3M-405.6% | -$147K-102.2% | $8.6M+90.3% | $3.1M-41.0% | $1.1M-81.2% | $6.7M+522.4% |
| Depreciation & Amortization | $325K+63.3% | $321K+98.3% | -$425K+25.0% | $548K+37.8% | $199K-43.2% | $162K-48.0% | -$567K-286.8% | $397K+34.3% |
| Stock-Based Compensation | N/A | $1.4M-43.1% | N/A | N/A | N/A | $2.5M+0.2% | N/A | N/A |
| Capital Expenditures | $68K-91.3% | $105K-10.5% | $155K-21.5% | $821K+83.3% | $777K+21.0% | $118K-33.1% | $198K+81.0% | $448K+1379.7% |
| Free Cash Flow | -$7.0M-188.9% | $339K-88.5% | -$3.4M-492.5% | -$968K-115.5% | $7.9M+101.7% | $3.0M-41.3% | $875K-84.4% | $6.3M+497.6% |
| Investing Cash Flow | -$1.6M+55.8% | -$2.1M+28.3% | $17.1M+727.4% | -$3.6M-2.9% | -$3.7M-18.1% | -$2.9M-30.9% | -$2.7M-22.7% | -$3.5M-45.3% |
| Financing Cash Flow | -$777K+75.0% | -$696K+14.3% | -$789K+15.7% | -$8.7M-558.8% | -$3.1M-280.8% | -$813K+22.4% | -$935K-106.5% | -$1.3M-128.0% |
| Dividends Paid | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% | $777K0.0% |
| Share Buybacks | N/A | N/A | N/A | $270K | N/A | N/A | N/A | N/A |
LFMDP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.8%+2.8pp | 88.2%+4.2pp | 84.3%+85.1pp | 87.7%-2.9pp | 86.1%-4.0pp | 84.0%-5.6pp | -0.8%-88.9pp | 90.6%+3.0pp |
| Operating Margin | -15.1%-10.3pp | -17.8%-15.5pp | -6.4%+51.9pp | -3.3%+4.2pp | -4.8%+7.7pp | -2.3%+11.7pp | -58.2%-53.4pp | -7.5%+4.3pp |
| Net Margin | -15.0%-11.7pp | -17.7%-17.3pp | -16.6% | -6.3%+2.4pp | -3.3%+10.3pp | -0.4%+15.0pp | 634.7% | -8.7%+7.1pp |
| Return on Equity | -88.9% | -59.0% | -24.3% | -289.6% | N/A | N/A | N/A | N/A |
| Return on Assets | -11.8%-9.6pp | -12.7%-12.4pp | -8.0%-64.3pp | -5.8%+0.6pp | -2.2%+8.6pp | -0.3%+10.8pp | 56.3%-3.1pp | -6.4%+8.6pp |
| Current Ratio | 0.90+0.1x | 1.04+0.2x | 1.25+0.5x | 0.73-0.1x | 0.77-0.1x | 0.82-0.2x | 0.78-0.4x | 0.83+0.1x |
| Debt-to-Equity | 6.52 | 3.66 | 2.04 | 47.64 | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.79+0.1x | 0.720.0x | 0.48+0.4x | 0.91+0.2x | 0.67-0.1x | 0.690.0x | 0.09-0.7x | 0.73-0.2x |
| FCF Margin | -14.8%-30.8pp | 0.7%-5.1pp | -10.1%-23.1pp | -1.6%-13.3pp | 16.0%+8.3pp | 5.8%-5.6pp | 13.0%+0.5pp | 11.7%+9.0pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock LFMDP | FY2025 | $194.1M | -$11.2M | -5.8% | N/A | 41/100 |
| CareCloud, Inc. 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock CCLDO | FY2025 | $120.5M | $11K | 0.0% | N/A | 46/100 |
| Aclarion, Inc. Warrant ACONW | FY2025 | $76K | -$7.2M | N/A | N/A | — |
| VSEE HEALTH INC VSEE | FY2025 | $14.6M | -$14.7M | N/A | $4.7M | — |
| OneMedNet Corp Warrant ONMDW | FY2025 | $1.4M | -$2.8M | N/A | N/A | 17/100 |
| Mangoceuticals, Inc. MGRX | FY2025 | $456K | -$20.6M | N/A | $8.7M | — |
Where LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock Ranks
Frequently Asked Questions
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's annual revenue?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's revenue growing?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.
Is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock profitable?
No, LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -5.8%.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's EBITDA?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's gross margin?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's operating margin?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's net profit margin?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's return on equity (ROE)?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) has a return on equity of -48.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's free cash flow?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's operating cash flow?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's total assets?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's capital expenditures?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's current ratio?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's debt-to-equity ratio?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had a debt-to-equity ratio of 2.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's return on assets (ROA)?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's Piotroski F-Score?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock's earnings high quality?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) reported a net loss of $11.2M while generating $8.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock cover its interest payments?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) reported an operating loss of $7.7M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock?
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.